Reduction of Platelets and Megakaryocytes in c-mpl-Deficient Mice

  • Mark W. Moore
  • Frederic J. de Sauvage
Part of the Contemporary Immunology book series (CONTIM)


The ability to treat various forms of cancer is often limited by the ability of patients to tolerate the dosing and frequency of chemotherapeutic agents. This is mostly caused by a loss of cells of hematopoietic origin, specifically red blood cells, neutrophils, and platelets. This results in anemia, increased susceptibility to infections, and the potential for severe bleeding episodes. Currently, there are cytokines that have the potential to address the loss of some of these cell types. Erythropoietin (EPO) is very effective in stimulating the production of red blood cells and granulocyte colony-stimulating factor (G-CSF) stimulates neutrophil production, thus it is possible to combat the anemia and neutropenia with cytokines that are approved for use in humans (although many of the precise indications related to cancer therapy are still in clinical trials). The treatment of the associated thrombocytopenia remains more problematic. To date, it can only be addressed by platelet transfusions, which has its own associated risks. For many years researchers have sought for a cytokine with the ability to specifically stimulate platelet production in a manner similar to EPO stimulation of red blood cells or G-CSF stimulation of white cells. Several cytokines, IL-3, IL-6, and IL-11 (1,2), have been shown to stimulate platelet production but the increase is relatively modest and there are potential side effects as these cytokines are not specific for platelets and stimulate a variety of responses. Clinical trials are underway with these cytokines to determine their benefit in treating thrombocytopenic patients.


Differential Cell Count Bone Marrow Smear Hematopoietic Origin Receptor Ligand System Megakaryocyte Growth 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gordon, M. S., and Hoffman, R. (1992) Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 80, 302–307.PubMedGoogle Scholar
  2. 2.
    Hoffman, R. (1989) Regulation of megakaryocytopoiesis. Blood 74, 1196–1212.PubMedGoogle Scholar
  3. 3.
    Souyri, M. Vigon, I., Penciolelli, J-F, Heard, J-M, Tamboruin, P., and Wendling, F. (1990) A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63, 1137–1147.Google Scholar
  4. 4.
    Vigon, I. M. Mornon, J.P., Cocault, L., Mitjavila, M. T., Tambourin, P., Gisselbrecht, S., Souyri, M. (1992) Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. USA 89, 5640–5644.Google Scholar
  5. 5.
    Methia, N., Louache, F., Vainchencker, W., and Wendling, F. (1993) Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 82, 1395–1401.PubMedGoogle Scholar
  6. 6.
    Gurney, A. L., Carver-Moore, K., de Sauvage, F. J., and Moore, M. W. (1994) Thrombocytopenia in c-mpl-deficient mice. Science 265, 1445–1447.Google Scholar
  7. 7.
    Ziegler, F. C. de Sauvage, F., Widmer, H. R., Keller, G. A., Donahue, C., Schreiber, R. D. (1994) In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 84 4045–4052.Google Scholar
  8. 8.
    Choi, E. S. Hokom, M., Bartley, T., Li Y. S., Ohashi, H., Kato T., (1995) Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl produces functional human platelets in vitro. Stem Cells Dayt. 13, 317–322.Google Scholar
  9. 9.
    Carver-Moore, K., Broxmeyer, H. E, Luoh, S.-M., Cooper, S., Peng, J., and Bernstein, S. A., et al. (1996) Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 88, 803–808.Google Scholar
  10. 10.
    de Sauvage, F., Hass, P., Spencer, S., Malloy, B., Gurney, A., and Spencer, S., et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 369, 533.Google Scholar
  11. 11.
    Lok, S. Kaushansky, K., Holly, R., Kuljper, J., Lofton-Day, C., and Oort, P., et al. (1994) Cloning and sequencing of murine thrombopoietin and stimulation of platelet production in vivo. Nature 369, 565.PubMedCrossRefGoogle Scholar
  12. 12.
    Bartley, T., Bogenbeger, J., Hunt, P., Li, Y., Lu, H., Martin, F., et al. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77, 1117–1124.Google Scholar
  13. 13.
    Kaushansky, K. Lok, S., Holly, R., Broudy, V., Lin, N., Bailey, M., et al. (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin. Nature 369, 568.Google Scholar
  14. 14.
    Wendling, F., Maraskovsky, E., Debili, N., Florindo, C., Teepe, M., Titeux, M., et al. (1994) cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 369, 571–574.Google Scholar
  15. 15.
    Broudy, V. C., Lin, N. L., and Kaushansky, K. (1995) Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakarocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85, 1719–1726.PubMedGoogle Scholar
  16. 16.
    de Sauvage, F., Carver-Moore, K., Luoh, S., Ryan, A., Dowd, M., Eaton, D., and Moore, M. (1996) Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J. Exp. Med., 183, 651–656.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Mark W. Moore
  • Frederic J. de Sauvage

There are no affiliations available

Personalised recommendations